LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastasesAmanda E.D. Van Swearingen, Carey K. Anders, Alan P. Hoyle et al.|Breast Cancer Research and Treatment|2018Cited by 48
LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).Carey K. Anders, Lisa A. Carey, Allison M. Deal et al.|Journal of Clinical Oncology|2017Cited by 4